Skip to content
OpenCapital
Get started

TTRX TTRX Cash & Equivalents

Cash & Equivalents at other companies

Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
$2.97B-4.0%
Bausch Health Companies logo
Bausch Health CompaniesBHC
$1.31B+13.4%
Journey Medical Corporation logo
Journey Medical CorporationDERM
$27.22M+29.2%
PTH
Pelthos Therapeutics Inc.PTHS
$31.98M+24,250%
Celldex Therapeutics logo
Celldex TherapeuticsCLDX
$35.73M+109%
Arcutis Biotherapeutics, Inc. logo
Arcutis Biotherapeutics, Inc.ARQT
$35.07M-34.7%

Other financials

Income statement

See full
Operating income-$1.2M-224%
Net income-$971.0K-196%
EPS (diluted)-$0.03-200%

Balance sheet

See full
Total debt$6.0M—
Total equity$6.1M+647%
Total assets$18.6M—

Cash flow

See full
Operating cash flow-$1.6M-448%

Valuation

See full
Market cap$217.45M-17.7%
Enterprise value$212.24M—

Returns & leverage

See full
Return on equity-118.8%—
Debt / equity1×—
Current ratio2.2×—

Where this comes from

Reported directly by TTRX in its filing.

Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents.

The official record: TTRX’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about TTRX's cash & equivalents.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is TTRX's cash & equivalents?
TTRX (TTRX) reported cash & equivalents of $11.22M in Q1 2026.
How has TTRX's cash & equivalents changed year-over-year?
TTRX's cash & equivalents increased by 613.3% year-over-year, from $1.57M to $11.22M.
What is the long-term trend for TTRX's cash & equivalents?
Over 2 years (2023 to 2025), TTRX's cash & equivalents has grown at a 107.3% compound annual growth rate (CAGR), from $1.18M to $5.08M.
What does cash & equivalents mean?
Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.